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Genetic variation and RNA structure regulate
microRNA biogenesis
Noemi Fernandez1,*, Ross A. Cordiner1,*, Robert S. Young1, Nele Hug1, Sara Macias1,w & Javier F. Ca´ceres1
MiRNA biogenesis is highly regulated at the post-transcriptional level; however, the role of
sequence and secondary RNA structure in this process has not been extensively studied.
A single G to A substitution present in the terminal loop of pri-mir-30c-1 in breast and gastric
cancer patients had been previously described to result in increased levels of mature miRNA.
Here, we report that this genetic variant directly affects Drosha-mediated processing of
pri-mir-30c-1 in vitro and in cultured cells. Structural analysis of this variant revealed an
altered RNA structure that facilitates the interaction with SRSF3, an SR protein family member
that promotes pri-miRNA processing. Our results are compatible with a model whereby a
genetic variant in pri-mir-30c-1 leads to a secondary RNA structure rearrangement that
facilitates binding of SRSF3 resulting in increased levels of miR-30c. These data highlight that
primary sequence determinants and RNA structure are key regulators of miRNA biogenesis.
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M
icroRNAs (miRNAs) are short non-coding RNAs that
negatively regulate the expression of a large proportion
of cellular mRNAs, thus affecting a multitude of cellular
and developmental pathways1,2. The canonical miRNA biogenesis
pathway involves two sequential processing events catalysed by
RNase III enzymes. In the nucleus, the microprocessor complex,
comprising the RNase III enzyme Drosha, the double-stranded
RNA-binding protein, DGCR8 and additional proteins carries out
the ﬁrst processing event, which results in the production of
precursor miRNAs (pre-miRNAs)3,4. These are exported to the
cytoplasm, where a second processing event carried out by
another RNase III enzyme, Dicer, leads to the production of
mature miRNAs that are loaded into the RISC complex5.
Due to the central role of miRNAs in the control of gene
expression, their levels must be tightly controlled. As such,
dysregulation of miRNA expression has been shown to result in
grossly aberrant gene expression and leads to human disease6–9.
In particular, the microprocessor-mediated step of miRNA
biogenesis has been shown to be regulated by multiple
signalling pathways, such as the transforming growth factor-b
pathway, leading to activation of subsets of individual miRNAs10.
Furthermore, altered miRNA expression has been associated with
the progression of cancer11,12, where a global downregulation of
miRNA expression is usually observed13,14. It was recently shown
that miRNA biogenesis can also be regulated in a cell-density-
dependent manner via the Hippo-signalling pathway, and that
the observed perturbation of this pathway in tumours may
underlie the widespread downregulation of miRNAs in cancer15.
Thus, miRNA production is tightly controlled at different levels
during the biogenesis cascade. Extensive evidence has shown that
RNA-binding proteins (RNA-BPs) recognize the terminal loop
(TL) of miRNA precursors and inﬂuence either positively or
negatively the processing steps carried out by Drosha in the
nucleus and/or Dicer in the cytoplasm. These include the hnRNP
proteins, hnRNP K and hnRNP A1, as well as the cold-shock
domain protein, Lin28 and the RNA helicases, p68/p72 (ref. 16).
In the case of the multifunctional RNA-BPs hnRNP A1, we have
previously shown that it can act as an auxiliary factor by
binding to the conserved TL of pri-miR-18a and promote its
microprocessor-mediated processing17,18. Conversely, the same
protein can act as a repressor of let-7 production in differentiated
cells19.
Several studies have shown that there is a correlation between
the presence of polymorphisms in pri-miRNAs and the
corresponding levels of mature miRNAs20; however, a
mechanistic understanding of how sequence variation and RNA
structure control miRNA biogenesis has not been explored in
great detail. Screening of novel genetic variants in human pre-
miRNAs linked to breast cancer identiﬁed two novel rare variants
in the precursors of miR-30c and miR-17, resulting in
conformational changes in the predicted secondary structures
and leading to altered expression of the corresponding mature
miRNAs. These patients were non-carriers of BRCA1 or BRCA2
mutations, suggesting the possibility that familial breast cancer
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Figure 1 | A genetic variant in the TL of hsa-pri-mir-30c-1 alters its normal expression. (a) Schematic representation of the hsa-pri-mir-30c-1 transcript
indicating the G to A mutation observed in breast and gastric cancer patients. Nucleotides (nt) encompassing primary (pri-miRNA; nt  159 to þ 161) and
pre-miRNA (nt þ 1 to þ 61) used in this experiment are indicated. Numbers are relative to the ﬁrst nt of the mature miRNA. (b) The relative expression
levels of mature miR-30c in MCF7 cells transfected with plasmids encoding either a WT sequence or one bearing the G/A mutation (n¼ 12). (c) Levels
of mature miR-30c in MCF7 cells transfected with in vitro-transcribed pri-mir-30c-1 (pri-miRNA) or an RNA oligonucleotide that mimics pre-miRr-30c-1
(pre-miRNA) sequences, either in a WT or G/A version (n¼ 5). Mann–Whitney U-test was used to evaluate differences between WT and G/A samples.
Error bars indicate s.e.m. **Po0.01. (d) Representative in vitro processing of pri-mir-30c-1 (380 nt) in MCF7 total cell extracts. Quantiﬁcation of
pre-miRNA band intensities are shown below and expressed as the relative intensity normalized to pre-miR-30c-1 WT variant.
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may be caused by variation in these miRNAs21. In particular, the
single-G to A substitution in primary miR-30c-1 (pri-mir-30c-1)
TL, which was also later observed in gastric cancer patients22,
results in an increase in the abundance of the mature miRNA.
Here, we investigate the mechanism by which the pri-mir-30c-1
variant detected in breast and gastric cancer patients results in
an increased expression of this miRNA. We found that this
genetic variant directly affects the microprocessor-mediated
processing of this miRNA. A combination of structural analysis
with RNA chromatography coupled to mass spectrometry
revealed changes in the pri-miRNA structure that lead to
differential binding of a protein factor, SRSF3, that has been
previously reported to act as a miRNA biogenesis factor. These
results provide a mechanism by which the pri-mir-30c-1 genetic
variant results in an increased expression of the mature miR-30c.
Altogether these data highlight that primary sequence as well as
RNA structure have a crucial role in the post-transcriptional
regulation of miRNA biogenesis.
Results
Enhanced processing of pri-mir-30c-1 G/A variant. To under-
stand the mechanism underlying miR-30c deregulation in breast
and gastric cancers, we investigated how the reported G27-to-A
mutation observed in a Chinese population might affect miRNA
biogenesis. It was previously shown that this substitution results
in an increase in the abundance of the mature miRNA; however,
the mechanism that leads to an increased expression is
unknown21,22. First, we transiently transfected MCF7 breast
cancer cells with constructs encoding 380 nucleotides of primary
hsa-pri-mir-30c-1 (pri-miRNA), either in a wild-type (WT)
version or bearing the G/A variant (Fig. 1a). We observed that the
G/A substitution resulted in increased levels of mature miR-30c
(Fig. 1b), resembling the situation observed in patients with this
mutation. Furthermore, this was not due to increased
transcription of the G/A-harbouring pri-miRNA, as shown by
unchanged pri-miRNA levels (Supplementary Fig. 1). To dissect
the precise step of miRNA biogenesis pathway that is affected by
the G/A substitution, we used an RNA version of pri-mir-30c-1
that has yet to undergo processing by the microprocessor in the
nucleus and by Dicer in the cytoplasm (pri-miRNA). As a
counterpart, we transfected an RNA oligonucleotide that mimics
the pre-miRNA, a sequence that arises upon processing by the
microprocessor. Importantly, we observed approximately a two-
three fold increase of miR-30c mature levels when transfecting
the G/A sequence derived from the pri-miRNA sequence,
whereas no changes were detected following transfection of the
pre-miRNA sequence (Fig. 1c). This experiment demonstrates
that the G/A substitution exclusively affects the Drosha-mediated
processing of the pri-miRNA. Moreover, we could recapitulate
this result in an in vitro reaction. We found that in vitro-
transcribed pri-mir-30c-1 was readily processed in the presence
of MCF7 total extracts, rendering a product of B65 nucleotidess
that corresponds to pre-mir-30c. Notably, the processing of the
G/A variant was increased, when compared to the WT version,
as was observed in living cells (Fig. 1d). The effect of the
G/A variation in the processing of pri-mir-30c-1 was also
recapitulated using a puriﬁed microprocessor (FLAG-Drosha/
FLAG-DGCR8 complex) and a shorter in vitro-transcribed
substrate (153 nucleotides; Supplementary Fig. 2). Altogether,
these complementary approaches indicate an enhanced micro-
processor-mediated processing of the G/A variant sequence and
this recapitulates what was previously observed in breast and
gastric cancer patients.
The sequence of pri-mir-30c-1 terminal loop is conserved.
Experiments described above conﬁrmed a crucial role for the
G27 residue in inﬂuencing miR-30c biogenesis. We analysed the
genomic variation in the hsa-pri-mir-30c-1 sequence across ver-
tebrates, and detected substantial evolutionary constraint across
the entire locus, as indicated by positive genomic evolutionary
rate proﬁling (GERP) scores (Fig. 2a). Constrained residues,
which highlight regions under purifying selection, are located in
the mature miRNA sequences in both arms, as expected due to
their effect in the regulation of gene expression. Interestingly, part
of the TL, where G27 is embedded, has also a very high level of
constraint, which is suggestive of a role of this sequence in
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Figure 2 | Sequence conservation of pri-mir-30c-1 precursors. (a) Nucleotide-level GERP scores across the locus, indicating extensive evolutionary
constraint. A GERP score above zero indicates signiﬁcant constraint, while a score below zero indicates an excess of nucleotide substitutions beyond the
expected neutral rate. The purple bars display the total number of observed nucleotide substitutions found in aligned sequences from 98 vertebrates.
D represents absence of the nucleotide from 98 vertebrate sequences analyzed. The location of the modiﬁed G/A nucleotide is indicated by a rectangle.
(b) Model of the predicted secondary structure with nucleotides coloured as in a to reﬂect their variation. Nucleotides present ino50% of the species are
indicated in lower case.
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miRNA biogenesis, as was previously described for a subset of
miRNAs16,18,23. In addition, residues at the 50end (nucleotides
 1 to  8;  11 to  16 and  20 to  23) and the 30end
(nucleotides þ 1 to þ 16 and þ 18 to þ 25) are also highly
constrained. Indeed, several of these residues were included as
part of the stem in the in silico predicted RNA structure
suggesting their importance for maintaining the RNA secondary
structure (Fig. 2b). These data led us to focus our attention on
these invariant sequences as potentially having a crucial role in
the regulation of miR-30c biogenesis.
Altered RNA structure of pri-mir-30c-1 G/A variant. Next, to
establish the importance of the G27-to-A substitution in RNA
structure, we performed structural analysis by selective
20-hydroxyl acylation analysed by primer extension (SHAPE)24.
This approach allows performing quantitative RNA structural
analysis at single-nucleotide resolution and is mostly independent
of base composition. While highly reactive residues are located at
single- stranded regions, non-reactive nucleotides are involved in
base pairs, non-Watson–Crick base pairs, tertiary interactions or
single stacking interactions in the C20-endo conformation25. To
this end, in vitro-transcribed RNA comprising 380 nucleotides of
pri-miR-30c-1 (either WT or the G/A variant sequence) was
treated with N-methylisatoic anhydride (NMIA), which reacts
with the 20hydroxyl group of ﬂexible nucleotides (Fig. 3a). Gross
modiﬁcations of SHAPE reactivity were observed in speciﬁc
regions of the G/A variant, when compared with the WT
sequence. The resulting proﬁles revealed a decreased SHAPE
reactivity in the TL (residues 28–30), with a concomitant increase
in the 50 region ( 18,  16 and  15) as well as in the 30end
(nucleotides þ 11, þ 16 and þ 19; Fig. 3a,b). This result
indicated the presence of different conformations in the pri-
miRNA with the G to A substitution, as compared to its WT
counterpart. To gain more information into the folding and
tertiary structure of this pri-miRNA, we assessed the solvent
accessibility of each nucleotide by hydroxyl radical cleavage
footprinting, generated by reduction of hydrogen peroxide by
iron (II)26. Hydroxyl radicals break the accessible backbone of
RNA with no sequence dependence. We deﬁned buried regions,
as zones with more than two consecutives nucleotides having a
reactivity (R) smaller than the mean of all reactivity, whereas
exposed regions are those with more than two consecutive
nucleotides having R larger than the mean of all reactivity. We
observed that the WT sequence presents two buried regions
located between nucleotides þ 8 to þ 40 and þ 9 to þ 25, as well
as two exposed segments between nucleotides  25 to þ 7 and
nucleotides þ 40 to þ 8 (Supplementary Fig. 3a). The G to A
substitution caused changes in the exposure to solvent, with both
the TL (nucleotides þ 28 to þ 40) and also the 30end region
(nucleotides þ 17 to þ 22) becoming solvent accessible. By
contrast, the 50end (nucleotides  7 to þ 7) and a small region in
miRNA-3p (nucleotides þ 55 to þ 58) are no longer solvent
accessible.
Altogether, the SHAPE and radical hydroxyl data suggest that
the G27A substitution is indeed affecting the RNA ﬂexibility of
pri-miRNA-30c-1, modifying both base-pairing interaction as
well as solvent accessibility of the nucleotides located in the TL
and in the basal region of the stem. This could be a consequence
of a long-distance interaction disruption between those regions
(Fig. 3c and Supplementary Fig. 3b), which could in turn modify
the interaction with RNA-BPs important for miR-30c biogenesis.
SRSF3 binds to a basal region of hsa-pri-mir-30c-1. A working
model is that either a repressor of microprocessor-mediated
processing binds to the WT sequence or, alternatively, the change
in RNA structure induced by the G/A sequence variation could
lead to the binding of an activator. To identify RNA-BPs that
differentially bind to either the pri-miR-30c-1 WT or G/A
sequence, we performed RNase-assisted chromatography fol-
lowed by mass spectrometry in MCF7 total cell extracts27. This
resulted in the identiﬁcation of 12 proteins that interact with the
WT sequence and 8 that bind to the G/A variant, being 7
common between both substrates. Signiﬁcantly, several of the
common proteins were previously implicated in miRNA
biogenesis and/or regulation, including the heat shock cognate
70 protein5, the hnRNP proteins, hnRNP A1 (refs 17,19) and
hnRNP A2/B1 (ref. 28), the RNA helicase DDX17 (ref. 4),
poly adenosine diphosphate ribose (ADP-ribose) polymerase 1
(PARP)29, and the RNA-BPs fused in sarcoma/translocated in
liposarcoma (FUS/TLS; Fig. 4a and Supplementary Fig. 4a). We
could validate some of the interactors using immunoprecipitation
followed by western blot analysis (Supplementary Fig. 4b).
FUS/TLS interacts with the WT sequence but it has been
previously shown that it acts to promote miRNA biogenesis by
facilitating the co-transcriptional recruitment of Drosha30. Thus,
this would not be compatible with a repressive role of pri-mir-
30c-1 WT processing. By contrast, in the case of the G/A variant,
we identiﬁed a single exclusive interactor, SRSF3, which is a
member of the SR family of splicing regulators. These family of
proteins are involved in constitutive and alternative splicing, but
some of them have been shown to fulﬁl other cellular
functions31,32. Importantly, SRSF3 had been previously reported
to be required for miRNA biogenesis33, which would be
compatible with a role as an activator of miRNA processing.
Therefore, we focused on a putative role of SRSF3 as an activator
of the processing of the G/A variant of pri-mir-30c-1. We could
validate this interaction by RNA chromatography followed by
western blot analysis with an antibody speciﬁc for SRSF3
(Fig. 4b). We also observed preferential binding of endogenous
SRSF3 protein to the G/A variant of pri-mir-30c-1, as shown by
immunoprecipitation of SRSF3 followed by quantitative reverse
transcription PCR (RT-qPCR) quantiﬁcation of the associated
pri-miRNA (Fig. 4c). To analyse the interaction of SRSF3 with
pri-miR-30c-1 WT and G/A sequences, we carried out toeprint
and SHAPE assays using SRSF3 protein puriﬁed from MCF7
cells. Toeprint analysis was performed with ﬂuorescent-labelled
antisense primers and capillary electrophoresis34. In this assay,
bound SRSF3 will block the reverse transcriptase and will
illuminate the site where SRSF3 is bound to RNA. Prominent
toeprint of SRSF3 with the G/A sequence was observed around
nucleotides Aþ 25–Gþ 24 (RNA size 170 nucleotides, position
Aþ 25; Fig. 4d). Similarly, analysis of SHAPE reactivity in the
presence of added puriﬁed SRSF3, revealed a dose-dependent
protection from NMIA attack upon addition of SRSF3 in speciﬁc
RNA residues in a dose-dependent manner (nucleotides  19,
 18, þ 16,þ 18,þ 19) of the basal region of G/A (Fig. 4f,e). Of
importance, a conserved CNNC motif ((N signiﬁes any
nucleotide), nucleotides from þ 16 to þ 22), previously
described as SRSF3 binding site33,35,36 is located within the
recognition place. Together, we can conclude that the interaction
of SRSF3 with pri-miR-30c-1 takes place at the CNNC motif at
the basal region of the G/A variant.
SRSF3 increases processing of pri-mir-30c-1 G/A variant. As
previously described, SRSF3 was proposed to have a role in
miRNA biogenesis by recognition of a CNNC motif located 17
nucleotides away from Drosha cleavage site33. Pri-mir-30c-1 has
two overlapping CNNC motifs (residues from þ 16 to þ 21).
Notably, accessibility around this region increased in the G/A
variant, as determined by SHAPE and hydroxyl radical analysis
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Figure 3 | Structural analysis reveals the importance of the G to A substitution in pri-mir-30c-1. (a) Values of SHAPE reactivity (depicted using colour
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(Fig. 3 and Supplementary Fig. 3). Furthermore, toeprint and
SHAPE assays in the presence of puriﬁed SRSF3 protein
conﬁrmed the speciﬁc recognition of the CNNC motif by
SRSF3 in a dose-dependent manner (Fig. 4). Next, we
addressed whether the preferential binding of SRSF3 to the pri-
mir-30c G/A variant sequence was responsible for its increased
expression by comparing the mature levels of miR-30c-1 WT or
G/A variant under variable levels of SRSF3 expression. To this
end, we co-transfected pri-mir-30c-1 constructs in MCF7 cells
under transiently overexpression of SRSF3, or alternatively,
transfected speciﬁc siRNAs to knock-down endogenous SRSF3
protein (Supplementary Fig. 5a,b). Of interest, we observed that
reduced levels of SRSF3 drastically decreased the levels of the G/A
miR-30c variant, without affecting the levels of WT miR-30c
(Fig. 5a, compare WT versus G/A panels). By contrast, transient
overexpression of SRSF3 increased signiﬁcantly the levels of WT
mature miR-30c, but has a more modest effect on the G/A variant
sequence. Altogether, these experiments suggest that SRSF3
binding is limiting in the WT scenario and that is essential to
promote miRNA biogenesis in the G/A context.
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To conﬁrm the role of SRSF3 in the differential processing
observed with pri-mir-30c-1 G/A variant sequence, we proceeded
to mutate the two consecutive CNNC motifs that are the natural
binding sites for SRSF3 (Fig. 5b). We generated a set of mutants
that affected either the ﬁrst or second CNNC motif (mut1 and
mut2, respectively) or a deletion of both motifs (DCNNC). The
CNNCmut1 carrying a double substitution Cþ 15Uþ 17 to AA, led
to a severe reduction in the levels of miR-30c expression only
with the G/A variant sequence (Fig. 5b). Similarly, a double
substitution of the second CNNC motif Gþ 20Cþ 21 to AA
(CNNCmut2) behaved similarly, exclusively affecting the G/A
variant. Importantly, we were also able to show that a knock-
down of SRSF3 expression affects the processing of pri-mir-30c-1
G/A variant, as expected; yet it does not compromise the
processing of pri-mir-30c-1 G/A variant that lacks the CNNC
motif (pri-mir-30c-1 G/A DCNNC; Supplementary Fig. 5c).
Thus, deletion of the CNNC motif in the G/A variant does indeed
reduced processing of pri- to pre-miR-30c-1 G/A variant;
however, the effect of decreasing SRSF3 is only seen when the
CNNC motifs are present. Altogether, these experiments strongly
suggest that the binding of SRSF3 is an important determinant of
miR-30c expression. Finally, we could recapitulate the observa-
tion that SRSF3 binding is limiting for the processing of WT pri-
mir-30c-1 in an in vitro system, supplemented with puriﬁed
SRSF3 protein (Fig. 6). First, we found that the FLAG-Drosha/
FLAG-DGCR8 complexes used for the in vitro processing assays
contained residual levels of SRSF3 protein (Supplementary Fig. 6).
Thus, the relative higher processing of the G/A variant can be
explained by the preferential binding of SRSF3 present in the
reaction to this variant, as compared to the WT pri-mir-30c-1.
Importantly, addition of puriﬁed SRSF3 protein increases the
microprocessor-mediated production of WT pre-mir-30c-1
(Fig. 6a), whereas addition of puriﬁed SRSF3 to the G/A variant
(Fig. 6c) or to DCNNC variants that lack SRSF3 binding sites did
not affect the processing activity (Fig. 6b,d). This is reminiscent of
what was observed in MCF7 cells under variable levels of SRSF3.
Discussion
The central role of miRNAs in the regulation of gene expression
requires that their expression is tightly controlled. Indeed, the
biogenesis of cancer-related miRNAs, including those with a role
as oncogenes (‘oncomiRs’), or those with tumour suppressor
functions is often dysregulated in cancer12,14,37. Interestingly,
some miRNAs have been shown to display both tumour
suppressor and also oncogenic roles, depending on the cell type
and the mRNA targets38, as was described for miR-221, which
exerts oncogenic properties in the liver39 but also acts as a tumour
suppressor in erythroblastic leukaemias40. Furthermore, miR-375
has been shown to display a dual role in prostate cancer
progression, highlighting the importance of the cellular context
on miRNA function41.
Despite a more comprehensive knowledge on the role of RNA-
BPs in the post-transcriptional regulation of miRNA production,
there is only circumstantial evidence on how RNA sequence
variation and RNA structure impact on miRNA processing. There
are several reports showing that a single-nucleotide substitution
in the sequence of pre-miRNAs could have a profound effect in
their biogenesis. Nonetheless, there is limited information about
single-nucleotide polymorphisms (SNPs) in the TL region of pri-
miRNAs. A bioinformatic approach led to the identiﬁcation of 32
such SNPs in 21 miRNA loop regions of human miRNAs42. Some
studies have found a correlation between the presence of
polymorphisms in pri-miRNAs and expression levels of their
corresponding mature miRNAs, affecting cancer susceptibility, as
shown for miR-15/16 in chronic lymphocytic leukaemia43,44,
miR-146 in papillary thyroid carcinoma45 and miR196a2 in lung
cancer46. Another example is the ﬁnding of a rare SNP in pre-
miR-34a, which is associated with increased levels of mature miR-
34a. This could be of biological signiﬁcance since precise control
of miR-34a expression is needed to maintain correct beta-cell
function, thus this could affect type 2 diabetes susceptibility47.
The emerging picture is that human genetic variation could
indeed not only have a role in miRNA function by affecting
miRNA seed sequences and/or miRNA binding sites in the
30UTRs of target genes, but it can also contribute signiﬁcantly to
modulation of miRNA biogenesis20.
In this study, we focused on a rare genetic variation found in
the conserved TL of pri-mir-30c-1 (G27-to-A variant) that was
found in breast cancer and gastric cancer patients and leading to
increased expression of miR-30c (refs 21,22). There is
circumstantial evidence that miR-30c is involved in many
malignancies acting as tumour suppressor48,49 or as an
oncogene50–52. Indeed, predicted targets of miR-30c, include
phosphate and tensin homologue (PTEN) and ataxia
telangiectasia mutated (ATM) that represent key breast cancer
tumour suppressor genes21. Interestingly, a signiﬁcantly increased
risk of gastric cancer was observed in subjects with the
homozygote AA of pre-miR-30c, when compared with
heterozygote AG or homozygote GG carriers22. To understand
the mechanism underlying miR-30c deregulation in breast cancer,
we investigated how this mutation affects miRNA biogenesis. We
show that the G–A substitution in pri-mir-30c-1 directly affects
Drosha-mediated processing both in vitro as well as in cultured
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cells (Figs 1,5,6 and Supplementary Fig. 2). The conservation of
pri-mir-30c-1 sequences across vertebrate species highlights the
importance of the primary sequence in the TL, 50 and 30 regions
(Fig. 2), suggesting a crucial role in miRNA biogenesis. Indeed,
conserved sequences in TL have been shown to be important for
recognition by auxiliary factors23 as well as for DGCR8 binding53,
allowing efﬁcient and accurate miRNA processing. It has also
been shown that pri-miRNA tertiary structure is a major player in
the regulation of miRNA biogenesis, as observed for the well
characterized miR17-92 cluster54–56. Here, using SHAPE
structural analysis, in conjunction with solvent accessibility
analysis by hydroxyl cleavage, we found that the G/A sequence
variation leads to a structural rearrangement of the apical region
of the pri-miRNA affecting the conserved residues placed at the
basal part of the stem (Fig. 3 and Supplementary Fig. 3). This
demonstrates that pri-mir-30c-1 is organized as a complex and
ﬂexible structure, with the TL and the basal region of the stem
potentially involved in a tertiary interaction. Further work is
required to determine the existence of direct contacts between
these regions.
Interestingly, we also observed that this RNA structure
reorganization promotes the interaction with SRSF3, an SR protein
family member that was demonstrated to facilitate pri-miRNA
recognition and processing33, by recognizing the CNNC motif
located 17 nucleotides away from Drosha cleavage site. A recent
study aiming to identify novel determinants of mammalian
primary microRNA processing conﬁrmed that the CNNC
primary sequence motif selectively enhances the processing of
optimal-length hairpins. This study, also predicted that a fraction
of human SNPs will lead to alterations of pri-miRNA processing57.
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Pri-mir-30c-1 has two overlapping CNNC motifs (residues
from þ 16 to þ 21; Fig. 5b). Notably, accessibility around this
region increased in G/A variant (Fig. 3). Furthermore, toeprint
and SHAPE assays in the presence of puriﬁed SRSF3 protein
clearly demonstrated that SRSF3 is speciﬁcally recognizing the
CNNC motif in a dose-dependent manner (Fig. 4). Altogether,
data presented here suggest that binding of SRSF3 to the WT
sequence is limiting and that the structural reorganization
induced by the G/A substitution makes the SRSF3 binding sites
more accessible. Taking everything into account we propose a
model whereby a genetic variant in a conserved region within the
TL of pri-mir-30c-1 causes a reorganization of the RNA
secondary structure promoting the interaction with SRSF3, which
in turn enhances the microprocessor-mediated processing of pri-
mir-30c-1 leading to increased levels of miR-30c (Fig. 7). We
conclude that primary sequence determinants and RNA structure
are key regulators of miRNA biogenesis.
Methods
Plasmids constructions. A pri-mir-30c-1 construct was ampliﬁed from human
genomic DNA by PCR with speciﬁc primers 30c1s (50-CAAGTGGTTCTGTG
TTTTTATTG-30) and 30c1a (50-GTACTTAGCCACAGAAGCGCA-30) The
PCR product was digested with EcoRI and was subsequently cloned into the
pCDNA3.1 vector (ThermoFisher). The G27–to-A mutation was generated by a
two-step PCR strategy. First, pri-miR-30c-1 was ampliﬁed with a 30Cmut1 oligo
(50-CCTTGAGCTTACAGCTGAGAG-30) and 30c1s and with 30Cmut2 oligo (50-
CTCTCAGCTGTAAGCTCAAGG-30) and 30c1a. Both PCR products, were pur-
iﬁed (Qiagen), pooled and used as a template for ampliﬁcation with 30c1s and
30c1a primers. The resulting PCR product was cloned in pGEMt (Promega).
pGEMt G/A plasmid was digested with EcoRI for cloning into pCDNA3.1. The
CNNC motifs were subjected to site-speciﬁc mutagenesis by PCR ampliﬁcation58.
Brieﬂy, 10 ng of pri-miR30c-1 (WT or G/A) was PCR ampliﬁed with the desired
mutagenic oligonucleotide (mut1: 50-CTTCATTTGATGTTTTCCATGGC-30,
mut2: 50-CTTCTTTTTTTTTTTCCATGGC-30 or CNNC 50-CTTCAGATG
TTTTCCATGGC-30) and CNNCs primer (50-CTGCTTACTGGCTTATCG-30).
The PCR product was cleaned (Qiagen) and used as the 50-ﬂanking primer in a
second PCR with an equal molar amount of primer CNNCa (50-GATATCT
GCAGAATTCACTAG-30).
The product of the second PCR was digested with EcoRI (New England Biolabs),
puriﬁed by agarose gel electrophoresis and ligated to the large EcoRI fragments
of pri-mir-30c-1 to produce the desired constructs (CNNCmut1, mut2 and
DCNNC). All the sequences were conﬁrmed by automatic sequencing. A list
of oligonucleotide sequences used in this study is presented as Supplementary
Table 1.
Cell culture. MCF7 and HEK 293 T cells were grown in high glucose Dulbecco’s
modiﬁed Eagle’s medium (Invitrogen) supplemented with 10% (v/v) fetal calf
serum (Invitrogen) and penicillin-streptomycin (Invitrogen) and incubated at
37 C in the presence of 5% CO2. Cells were tested for mycoplasma contamination.
Transfections. MCF7 cells grown in 24-well plates were transfected with either
pri-mir-30c-1 (WT or G/A) constructs, in vitro-transcribed RNA (0.33 mg per 105
cells) or oligonucleotides-encoding pre-mir-30c (Sigma Aldrich)(50-UGUAAAC
AUCCUACACUCUCAGCUGUGAGCUCAAGGUGGCUGGGAGAGGGUUG
UUUACUCC-30) using Attractene (Qiagen), following manufacturer’s instruction.
pCDNA-3, pri-miR-30a or oligo30a (50-UGUAAACAUCCUCGACUGGAAGC
UGUGAAGCCACAAAUGGGCUUUCAGUCGGAUGUUUGCAGC-30) were
used as negative controls in DNA or RNA transfections, respectively. Cells extracts
were prepared at 8 or 48 h (after RNA/DNA addition) by direct lysis using 100 ml of
lysis buffer (50mM Tris-HCl at pH 7.8, 120mM NaCl, 0.5% NP40). For SRSF3
gene silencing/overexpression MCF7 cells grown in 15 cm dishes were transfected
with ON-TARGETplus siRNA (Dharmacon) or pCG. As negative controls, cells
were transfected with ON-TARGETplus Non-targeting siRNAs and pCG plasmid,
respectively. Cells were split in 24-well dishes 24 h after transfection and 24 h later
transfected with different versions of pri-miRNA constructs. HEK 293Ts were
grown to 70% conﬂuency in 6-well plates and then transiently co-transfected with
3 mg of FLAG-Drosha and 1 mg of FLAG-DGCR8, or 4mg FLAG-empty vector per
well. Cells were expanded for 24 h, then split to 10 cm plates and expanded for a
further 24 h before cells were scraped, collected and snap frozen until required.
Western blot analysis. Equal amounts of total protein (determined by Bradford
assay) were loaded in 12% NUPAGE gels (Invitrogen) and transferred to cellulose
membranes using IBLOT system (Invitrogen). Identiﬁcation of SRSF3 was per-
formed with a rabbit polyclonal antibody (RN080PW, Medical and Biological
Laboratory (MBL), Dilution 1:500), followed by a secondary horseradish perox-
idase-conjugated antibody and ECL detection (Pierce). Other primary antibodies
used in this study were: mouse monoclonal anti-PARP-1 antibody (E-8): sc-74469,
Santa Cruz Biotechnology, Dilution 1:500 ); Rabbit polyclonal anti-DDX17 anti-
body ((S-17): sc-86409, Santa Cruz Biotechnology, Dilution 1:500); Rabbit poly-
clonal anti-hnRNP A1 antibody (PA5-19431, Invitrogen antibodies, Dilution
1:500); Rabbit polyclonal anti-TLS/FUS antibody (ab23439, Abcam, Dilution
1:1,000).
In vitro transcription of pri-miRNA substrates. Before RNA synthesis, pri-mir-
30c-1 plasmids (WT and G/A variant) were linearized using ApaI (New England
Biolabs). In addition, shorter pri-mir-30c-1 probes were PCR ampliﬁed from
pri-mir-30c-1 plasmids (WT, G/A and their respective DCNNC counterparts) for
in vitro processing assays (Fig. 6 and Supplementary Fig. 1) using a forward primer
harbouring a T7-promoter sequence fused to a 19 nucleotide sequence com-
plementary to pri-mir-30c-1 (50-AATACGACTCACTATAGGGCTGATCAACC
CTGGACC-30) and a reverse primer (50- AGTGGAGACTGTTCCTTCTTC-30),
which when in vitro-transcribed generated a 153 nucleotides (CNNC) or 146
nucleotides (DCNNC) and then subsequently PCR puriﬁed (Qiagen) for in vitro
transcription. An aliquot of 1 mg of DNA or 400 ng of PCR product were in vitro
transcribed for 1–2 h at 37 C using 50U of T7 RNA polymerase (Roche) in the
presence of 0.5mM ribonucleoside tri-phosphates (rNTPs) and 20 U of RNAsin
(Promega). When needed, RNA transcripts were labelled using (a-32P)-UTP
(800 Ci per mmol, Perkin Elmer) and following DNAse treatment, unincorporated
32P-UTP was eliminated by exclusion chromatography in TE equilibrated columns
(GE Healthcare) or PAGE gel puriﬁcation, followed by phenol/chloroform and
ethanol precipitation.
SRSF3 puriﬁcation. Puriﬁcation of SRSF3 from MCF7 cells was performed fol-
lowing transient expression of epitope-tagged SRSF3 (ref. 59). Brieﬂy, MCF7 cells
were grown to conﬂuence in 15 cm dishes and transiently transfected with
pCG-T7-SRSF3 (ref. 60). Forty-eight hours after transfection cell pellets were
resuspended in 20ml of ice-cold lysis buffer (50mM NaP buffer, pH8, 0.5M Na Cl,
5mM b-glycerophosphate, 5mM KF, 0.1% Tween 20 and 1 protease inhibitor
cocktail) and sonicated ﬁve times 30 s followed by centrifugation at 16,000 g for
20min at 4 C. After centrifugation the supernatant was loaded into a
chromatography column (Biorad) previously prepared with T7 Tag antibody
Agarose (Novagen). The ﬂow-through was collected and loaded a second time. The
column was washed two times with 10ml of lysis buffer. Then, eluates were eluted
with 10 serial 0.8ml volumes of elution buffer (0.1M citric acid, pH 2.2, 5 mm
b-glycerophosphate c and 5mM KF) and collected in microcentrifuges tubes
containing 200 ml of 1M Tris pH 8.8 mixed and stored at 4 C. The fractions were
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Figure 7 | Model depicting the stimulatory effect of the G/A genetic
variant on pri-miRNA processing. Cartoon depicting a model whereby the
genetic variant identiﬁed in pri-mir-30c-1 leads to a secondary RNA
structure rearrangement that facilitates binding of SRSF3 resulting in
increased microprocessor-mediated processing of pri-mir-30c-1.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15114 ARTICLE
NATURE COMMUNICATIONS | 8:15114 | DOI: 10.1038/ncomms15114 | www.nature.com/naturecommunications 9
analysed on SDS–PAGE (Invitrogen) followed by Coomassie blue staining. The
eluates containing the protein were dialyzed overnight against BC100 buffer
(20mM tris, pH8, 100Mm KCl, 0.2mM EDTA pH8 and 20% glycerol), and stored
in aliquots at  80 C.
In vitro processing assays. Radio-labelled in vitro-transcribed pri-mir-30c-1
(50,000 c.p.m.) was incubated with 650 mg of MCF7 total cell extract61 (Fig. 1d),
or incubated with FLAG-tagged complexes immunopuriﬁed from HEK293T
(ATCC CRL-3216) cells transiently co-expressing FLAG-Drosha & FLAG-DGCR8
or FLAG-empty vector control, in the absence or RNase62 (Fig. 6 and
Supplementary Fig. 2). Additionally, in vitro processing reactions were
supplemented with increasing concentrations of immunopuriﬁed T7-SRSF3
(Fig. 6). The in vitro processing reactions were performed in the presence of buffer
A (0.5mM adenosine triphosphate (ATP), 20mM creatine phosphate and 6.4mM
MgCl2). Reactions were incubated for 1 h at 37 C and treated with proteinase K.
RNA was extracted by phenol/chloroform and ethanol precipitation. Samples were
resolved in an 8% 1 TBE polyacrylamide urea gel. An uncropped scan of the
experiment corresponding to Fig. 1d is provided as Supplementary Fig. 7a.
Pre-miRNA and mature miRNA qRT-PCR. One step qRT-PCR was used to
calculate pre-miR-30c-1 levels. Speciﬁcally, 300 ng of total RNA was used with
SuperScript III Platinum SYBR Green One-Step qRT-PCR Kit (Invitrogen, 11736-
051) on CFX96 real time system. Primers located within the precursor sequence of
miR30c (Fwd 50-TGTAAACATCCTACACTCTCAG-30 ; Rev – 50-GAGTAAAC
AACCCTCTCCCA-30) or within the primary sequence of miR30c (fwd 50-CA
GTGGTCAGGGGCTGAT-30 ; rev 50-GGAGTGGAGACTGTTCCTTCT-30) were
used to calculate pre-miR30c levels63. The relative amounts of mature miR-30c
present in total RNA samples were measured using Exiqon miRCURY LNA
following manufacturer’s instructions. Total RNA from cytoplasmic lysates was
isolated using RNAzol (Invitrogen) and RT was carried out with Universal RT
microRNA PCR (Exiqon) using 500 ng of RNA. A 1/20 dilution of the RT reaction
was used for qPCR with a speciﬁc microRNA LNA (Exiqon) primers set and the
LightCycler system with the FastStart DNA Master Green II (Roche). The amount
of miR-30c detected in the reaction was normalized by a parallel reaction
performed with U6 and SNOR48 primers. For SRSF3 gene silencing or
overexpression, MCF7 cells (ATCC HTB-22) grown in 15 cm dishes were
transfected with ON-TARGET plus siRNA (Dharmacon) or pCG. As negative
controls, cells were transfected with ON-TARGETplus Non-targeting siRNAs and
pCG-T7 plasmid, respectively. Cells were split in 24-well dishes 24 h after
transfection and 24 h later transfected with different versions of pri-miRNA
constructs.
Quantitative RNA co-immunoprecipitation. Lysates from pri-miR-30c-1 (WT
and G/A) transfected cells were pre-cleared with mouse IgG beads followed by
incubation with a polyclonal rabbit anti-SRSF3 antibody (MBL). The complexes
were pulled-down using protein G beads (Amershan), then treated with proteinase
K (Sigma) and RNA was extracted and puriﬁed using Trizol (Invitrogen)64.
qRT-PCR was carried out with superscriptIII (Invitrogen) RT using 500ng of RNA
as a template and the TL (50-GGAGTAAACAACCCTCTCCCAGC-30) and actin
(50-GGTCTCAAACATGATCTGGG-30) primers. Then a 1/20 dilution of the RT
reaction was used for qPCR with appropriate pairs of speciﬁcs primers (TL: 50-CA
TCCTACACTCTC-30 and 50-GGAGTAAACAACCCTCTCCCAGC-30 ,
actin: 50-GGGTCAGAAGGATTCCTATG-30 and 50-GGTCTCAAACATGATC
TGGG-30). Quantitative RNA co-immunoprecipitation values were calculated
according to the formula: qPCR value TL mRNA immunoprecipitation/qPCR
value TL mRNA total)/(qPCR value control mRNA immunoprecipitation/qPCR
value control mRNA total). An uncropped scan of the experiment corresponding
to Fig. 4b is provided as Supplementary Fig. 7b.
Phylogenetic conservation. The alignment of 98 vertebrate sequences of
pri-mir-30c-1 were retrieved from USCS genome browser. Each nucleotide
frequency was plotted in a heat map.
Evolutionary constraint. Evolutionary constraint was quantiﬁed for individual
nucleotide positions as the number of rejected substitutions, as calculated by the
GERPþ þ algorithm. This data was extracted from the UCSC genome browser,
where they had been calculated over their 36-way mammalian genome alignments.
RNA structure analysis. RNA structure models as shown on Figs 2b and 3c
were obtained using RNAstructure software (http://rna.urmc.rochester.edu/
RNAstructureWeb/).
SHAPE analysis. Pri-mir-30c-1 RNA was treated with NMIA (Invitrogen), as the
modifying agent65. For primer extension, equal amounts of NMIA treated and
untreated RNA (0.5 pmols) were incubated with 2 pmol of 50-end ﬂuorescently
labelled primer (50-CTAGATGCATGCTCGAGCG-30). NED ﬂuorophore was used
for both, treated and not treated RNAs while VIC ﬂuorophore was used for the
sequencing ladder. cDNA products were resolved by capillary electrophoresis. Pri-
miR-30c-1-SRSF3 complexes were assembled in folding buffer (100mM HEPES
pH 8, 6mM MgCl2) using 170 nM RNA in the presence of increasing amounts of
puriﬁed SRSF3 protein (260 and 500 nM). Then, RNA alone or pre-incubated with
SRSF3 was treated with NMIA. RNA was phenol extracted and ethanol precipitated
and then subjected to primer extension analysis.
Hydroxyl radical footprinting. Pri-mir-30c-1 RNA was subjected to Hydroxyl
radical footprinting. Brieﬂy, 1.7 pmol of RNA was denatured and folded in folding
buffer (40mM MOPS pH 8.0, 80mM KOAc, and 0.0.5 or 6mM MgCl2). Samples
were incubated with 1 ml of the Fe(II)–EDTA complex, 1 ml of sodium
ascorbate and 1 ml of hydrogen peroxide for 30 s at 37 C. Fe(II)–EDTA (7.5mM
Fe(SO4)2(NH4)2  6H2O and 11.25mM EDTA, pH 8.0), 0.3% hydrogen peroxide
and 150mM sodium ascorbate solutions were freshly prepared. As a control a
lacking Fe(II)–EDTA reaction was performed66. Samples were quenched and
precipitated by addition of one-third of 75% glycerol, 1 ml of 20mgml 1 glycogen,
1 ml of 3M NaCl, 2 ml of 0.5M EDTA and 2.5 volumes of ice-cold ethanol. RNAs
were re-suspended and reverse-transcribed using ﬂuorescent primers as described
for SHAPE reactivity. cDNA products were resolved by capillary electrophoresis.
SHAPE reactivity and Hydroxyl radical cleavage data analysis. SHAPE
electropherograms of each RT were analysed using the quSHAPE software67. Then,
data from 10 independent assays were used to calculate the mean of SHAPE
reactivity. To minimize the technical variation, each RT stop quantitative value was
normalized to the total intensity of the average of 10 highly reactive nucleotides in
the reaction. Grubbs’ test was used to identify outliers. To obtain SHAPE
differences between pri-mir-30c WT and GA or Free RNA and RNA-SRSF3
complexes, the SHAPE reactivity values obtained in WT or free RNA were
subtracted from the reactivity values obtained in GA or in the presence of the
protein. The statistical analysis was performed by Mann–Whitney U-test. Only
nucleotides with absolutes differences larger than 0.25 and statistically signiﬁcant
were considered. Hydroxyl radical cleavage intensities of each reaction were also
analysed using quSHAPE software66. Then, data from six independent assays were
used to calculate the mean of hsa-pri-mR-30c WT or GA cleavage. Grubbs’ test was
used to identify outliers. Buried regions were deﬁned as zones with more than two
consecutives nucleotides having a reactivity (R) smaller than the mean of all
reactivity, whereas exposed regions are those with more than two consecutive
nucleotides having R larger than the mean of all reactivity.
Toeprint assays. Pri-mir-30c-1: SRSF3 complexes were assembled as described
for SHAPE analysis. After protein incubation samples were subsequently
subject to primer extension using ﬂuorescent primer (NED)
50-CTAGATGCATGCTCGAGCG-30 .pri-miR-30c (ref. 34). Primer extension
products were extracted with phenol, and ethanol precipitated pellets were
resuspended in 5 ml of HI-Di formamide (ThermoFisher), which included 0.5 ml of
GeneScan 500 Liz dye size standards. The products were separated by capillary
electrophoresis and analysed by GeneMarker software.
RNA chromatography. RNase-assisted RNA chromatography with RNAse A/T1
was performed, using in vitro-transcribed pri-mir-30c-1 and total MCF7 cell
extracts28. RNA-bound proteins were separated using 4–12% NUPAGE bis–tris
system (Invitrogen) and individual lanes were subjected to mass spectroscopy
(BSRC Mass Spectrometry and Proteomics Facility, University of St Andrews).
Results were conﬁrmed by western blot analysis with anti-SRSF3 (MBL),
anti-PARP-1 (Santa Cruz), anti-DDX17 (Santa Cruz), anti-hnRNPA1 (Thermo
Scientiﬁc) and anti-FUS (Abcam) speciﬁc antibodies, as indicated above (Western
blot analysis section).
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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